SEI Investments
HRTX icon

SEI Investments’s Heron Therapeutics HRTX Stock Holding History

SEI Investments’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1K Hold
12,685
– – ﹤0.01% 3228
2025
Q4 		$16.5K Hold
12,685
– – ﹤0.01% 3116
2025
Q3 		$16K Hold
12,685
– – ﹤0.01% 2812
2025
Q2 		$26.3K Hold
12,685
– – ﹤0.01% 2776
2025
Q1 		$27.9K Hold
12,685
– – ﹤0.01% 2722
2024
Q4 		$19.4K Sell
12,685
-2,118
-14% -$3.43K ﹤0.01% 2713
2024
Q3 		$29.5K Buy
14,803
+2,118
+17% +$5.06K ﹤0.01% 2656
2024
Q2 		$44.4K Buy
+12,685
New +$39K ﹤0.01% 2595
2023
Q2 		– Sell
-18,138
Closed -$27.4K – 2712
2023
Q1 		$27.4K Buy
+18,138
New +$45.4K ﹤0.01% 2651
2022
Q1 		– Sell
-394,473
Closed -$3.6M – 2616
2021
Q4 		$3.6M Buy
394,473
+68,523
+21% +$700K 0.01% 1311
2021
Q3 		$3.48M Sell
325,950
-25,061
-7% -$305K 0.01% 1266
2021
Q2 		$5.49M Buy
351,011
+78,053
+29% +$1.24M 0.01% 1028
2021
Q1 		$4.42M Sell
272,958
-142,258
-34% -$2.54M 0.01% 1085
2020
Q4 		$8.79M Sell
415,216
-49,022
-11% -$852K 0.02% 698
2020
Q3 		$6.88M Buy
464,238
+337,721
+267% +$5.27M 0.02% 721
2020
Q2 		$1.86M Sell
126,517
-1,184
-0.9% -$19.5K 0.01% 1301
2020
Q1 		$1.5M Buy
127,701
+95,120
+292% +$1.79M 0.01% 1271
2019
Q4 		$791K Sell
32,581
-504
-2% -$11.2K ﹤0.01% 1736
2019
Q3 		$590K Buy
+33,085
New +$609K ﹤0.01% 1806
2018
Q3 		– Sell
-29,560
Closed -$1.15M – 2895
2018
Q2 		$1.15M Buy
+29,560
New +$941K ﹤0.01% 1524
2017
Q2 		– Sell
-2,299
Closed -$34K – 3166
2017
Q1 		$34K Buy
2,299
+188
+9% +$2.6K ﹤0.01% 2221
2016
Q4 		$28K Buy
2,111
+6
+0.3% +$94 ﹤0.01% 2272
2016
Q3 		$36K Buy
+2,105
New +$39.1K ﹤0.01% 2145
2015
Q4 		– Sell
-11,483
Closed -$280K – 2596
2015
Q3 		$280K Buy
+11,483
New +$383K ﹤0.01% 1500

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

SEI Investments's HRTX Position: Q1 2026 in Review

SEI Investments held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 12,685 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3228.

SEI Investments first reported a position in HRTX in Q3 2015 and has held it in 24 quarters since. The position peaked at $8.79M in Q4 2020. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • SEI Investments held 12,685 shares of Heron Therapeutics worth $10.1K as of Q1 2026.
  • SEI Investments left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #3228 holding.
  • SEI Investments first reported a position in Heron Therapeutics in Q3 2015 and has held it in 24 quarters since.
  • SEI Investments's Heron Therapeutics position peaked at $8.79M in Q4 2020.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.